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In vitro Models of Bone Remodelling
and Associated Disorders
Robert Owen and Gwendolen C. Reilly*
Department of Materials Science and Engineering, University of Sheffield, Insigneo Institute for in silico Medicine, Sheffield,
United Kingdom
Disruption of bone remodelling by diseases such as osteoporosis results in an imbalance
between bone formation by osteoblasts and resorption by osteoclasts. Research into
these metabolic bone disorders is primarily performed in vivo; however, in the last decade
there has been increased interest in generating in vitro models that can reduce or
replace our reliance on animal testing. With recent advances in biomaterials and tissue
engineering the feasibility of laboratory-based alternatives is growing; however, to date
there are no established in vitro models of bone remodelling. In vivo, remodelling is
performed by organised packets of osteoblasts and osteoclasts called bone multicellular
units (BMUs). The key determinant of whether osteoclasts form and remodelling occurs is
the ratio between RANKL, a cytokine which stimulates osteoclastogenesis, and OPG, its
inhibitor. This review initially details the different circumstances, conditions, and factors
which have been found to modulate the RANKL:OPG ratio, and fundamental factors
to be considered if a robust in vitro model is to be developed. Following this, an
examination of what has been achieved thus far in replicating remodelling in vitro using
three-dimensional co-cultures is performed, before overviewing how such systems are
already being utilised in the study of associated diseases, such as metastatic cancer
and dental disorders. Finally, a discussion of the most important considerations to be
incorporated going forward is presented. This details the need for the use of cells capable
of endogenously producing the required cytokines, application of mechanical stimulation,
and the presence of appropriate hormones in order to produce a robust model of bone
remodelling.
Keywords: osteoblast, osteoclast, co-culture, tissue engineering, 3D cell culture, bone remodelling, in vitromodel,
osteoporosis
INTRODUCTION
Bone remodelling occurs throughout life and is an essential physiological process that renews
the skeleton. It maintains or improves bone strength by replacing primary, immature bone and
old, micro-damaged or fractured bone, as well as maintaining calcium homeostasis (Boyce et al.,
2012). The resorption and formation processes are balanced, and remodel approximately 5% of
cortical and 20% of trabecular bone each year. Whilst the latter accounts for only 25% of the total
bone volume, the increased surface area to volume ratio results in a 10 times higher metabolic
rate (Fernández-Tresguerres-Hernández-Gil et al., 2006). It is a continuous event throughout life,
but the balance between resorption and formation changes. In healthy individuals, formation
dominates for the first three decades until peak bone mass is achieved (Kini and Nandeesh, 2012).
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This bone mass is then maintained for approximately 20 years
until resorption begins to outweigh formation and mass declines.
In contrast to remodelling, a homeostatic renewal process
where resorption and formation are coupled spatially and
temporally, bone modelling defines the shaping or reshaping of
bones where osteoblasts and osteoclasts can act independently.
This begins before birth and is most apparent during skeletal
development and in young adults; however, it still occurs later in
life in response to mechanical load (Langdahl et al., 2016; Paiva
and Granjeiro, 2017).
The Cellular and Molecular Basis of Bone
Remodelling
Remodelling occurs via basic multicellular units (BMUs). These
are composed from discrete packets of osteoclasts and osteoblasts
accompanied by a blood supply and supporting connective tissue
(Jilka, 2003). BMUs form and refill tunnels through cortical bone
and in trabecular bone they create trenches on the surface. The
osteoclasts are at the front, forming the cutting cone or hemi-
cone in the case of trabecular BMUs, with osteoblasts behind
forming the closing cone or hemi-cone. The BMU can move in
all three axes in cortical BMUs and two axes in trabecular BMUs
as they are on the surface (Parfitt, 2002; Clarke, 2008) (Figure 1).
Whilst osteoblasts and osteoclasts are directly involved in
the bone remodelling process, they are not the only bone cells
involved. Osteoblast precursors present in the bone marrow,
often referred to as mesenchymal progenitors, mesenchymal
stromal cells or mesenchymal stem cells (MSCs), are required
to differentiate into osteoblasts and support osteoclast formation
(Rucci, 2008; Lindner et al., 2010). Osteocytes are terminally
differentiated osteoblasts that become embedded in the bone
during formation in pits called lacunae. They are star shaped
(stellate) with multiple cytoplasmic extensions (Tanaka-Kamioka
et al., 1998) that occupy the canaliculi that connect the lacunae
and make contact with other osteocytes, osteoblasts, cells lining
the bone surface, and vasculature via gap junctions (Doty, 1981;
Dallas et al., 2013). This network of osteocytes forms a complex
communication system that enables them to sense and respond
to stresses placed upon the bone by releasing paracrine factors
that regulate bone remodelling (Santos et al., 2009; Paiva and
Granjeiro, 2017).
The action of osteoblasts and osteoclasts within the
BMU is tightly coupled via biochemical pathways. Once
osteoclast precursors have arrived at the remodelling site
from the bloodstream or surrounding marrow, two factors are
predominantly responsible for their maturation into osteoclasts:
macrophage-colony stimulating factor (M-CSF) and receptor
activator of nuclear factor kappa-B ligand (RANKL). These
factors bind to their respective receptors on the precursors,
colony-stimulating factor-1 receptor (c-fms) and receptor
activator of nuclear factor kappa-B (RANK), and initiate
osteoclastogenesis. The binding of RANKL to RANK can be
antagonised by osteoprotegerin (OPG), a decoy receptor for
RANKL that inhibits osteoclastogenesis. Therefore, whether and
how much resorption occurs is determined by the RANKL:OPG
ratio (Mizuno et al., 1998). Like RANKL, OPG is also produced
by osteoblasts meaning that they have a key role in controlling
the balance between bone formation and resorption (Figure 2).
Although the RANK/RANKL/OPG axis is perhaps the best
characterised mediator of bone remodelling, it is not the only
method by which the constituent cells communicate and the
process is controlled. For example, bone morphogenetic proteins
(BMPs) can induce osteogenic differentiation and modulate
osteoclast fate (Valcourt and Moustakas, 2005), Eph/epherin
signalling by osteoclasts can promote or inhibit osteoblastic
differentiation depending on the ligand type (Matsuo and Otaki,
2012) and growth hormone and insulin-like growth factors can
moderate remodelling (Giustina et al., 2008). Recently the role of
extracellular vesicles (EVs) in intercellular communication is of
particular interest. These can carry multiple types of cargo (e.g.,
DNA, RNA, proteins, lipids), with bone-related EVs transporting
molecules such as BMPs, non-collagenous extracellular matrix
proteins such as osteocalcin, RANKL and OPG, and microRNAs
that can promote or inhibit osteoblastic differentiation (Xiao
et al., 2007; Deng et al., 2015; Liu et al., 2018). This type
of signalling has been identified between multiple cell types
involved in bone remodelling, including: MSCs and osteoblasts,
osteoblasts and osteoclasts, osteocytes and osteoblasts, and
osteoclasts and osteoclasts. However, as the precise roles of EV
signalling are still being investigated, it is not something that is
commonly examined in vitro when studying bone remodelling.
Therefore, this review predominantly focusses on the roles of
RANKL and OPG. Work performed to date on EVs involved in
remodelling has recently been comprehensively reviewed by Liu,
et al., and Yuan, et al., (Liu et al., 2018; Yuan et al., 2018).
The earliest haematopoietic precursor that can give rise to
an osteoclast is the granulocyte-macrophage colony forming
cell (GM-CFU). M-CSF is produced by osteoblasts and stromal
cells and its activation of c-fms promotes the survival and
proliferation of the GM-CFU (Ross, 2006; Hodge et al., 2007).
RANKL is expressed by osteoblasts, T cells, and endothelial
cells and its conjugation with RANK commits the GM-CFU
to the osteoclast lineage. This upregulates key markers such
as tartrate-resistant acid phosphatase 5b (TRAP), the osteoclast
specific isoform of tartrate-resistant acid phosphatase (Halleen
et al., 2000). Continued exposure to both factors stimulates
the preosteoclasts to fuse and form a multinucleated cell. Once
activated, they bind to the bone surface and secrete hydrogen
ions and proteolytic enzymes to degrade the mineral and organic
components of bone, respectively, forming a resorption pit (Bull
et al., 2002; Kular et al., 2012). Therefore, active osteoclasts can
be identified by three features: the presence of TRAP, multiple
nuclei, and the capability to resorb bone.
It has recently been discovered that trabecular BMUs are
separated from the surrounding bone marrow by a canopy to
create a bone remodelling compartment (BRC). These canopies
are likely formed by an extension of the bone-lining cells due
to their expression of typical osteoblastic markers. The BRC
generates a unique microenvironment conducive to paracrine
signalling and facilitates BMU formation and function. It allows
control over osteoblast-osteoclast coupling and ensures tightly
regulated remodelling. BRCs cover practically all resorptive
surfaces and over 50% of formative surfaces, indicating that
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FIGURE 1 | Bone multicellular units in (top) trabecular and (bottom) cortical bone. In trabecular bone they initiate underneath bone remodelling canopies formed from
bone lining cells and in cortical bone at points within Haversian canals.
they form as resorption initiates and are closed as formation
completes. Capillaries penetrate the BRC and are thought to
serve as conduits for the precursor cells needed to form and
maintain BMUs as their lifespan is 6 to 9 months, much longer
than the constituent cells (osteoclasts 2 weeks, osteoblasts 3
months). Furthermore, pericytes adhering to the walls of this
vasculature are also able to undergo osteogenic differentiation
(Henriksen et al., 2014). Disruption of the BRC negatively
affects bone turnover and can result in uncoupled remodelling,
where bone is resorbed without being replaced (Hauge et al.,
2001; Parfitt, 2001; Andersen et al., 2009; Eriksen, 2010;
Raggatt and Partridge, 2010; Delaisse, 2014; Wesseling-Perry,
2014).
The Stages of Bone Remodelling
The current perception of bone remodelling is that it can
be divided into five sections, although the nomenclature
for each division is not universal. Herein, they will be
referred to quiescent, activation, resorption, formation, and
mineralisation (Figure 3). Quiescent describes inactive bone
prior to remodelling initiation. Then, as a result of events
such as microfracture, mechanical loading, or low calcium due
to pregnancy or a deficient diet, the activation phase begins.
This prepares the bone for remodelling by forming the BRC
and recruiting osteoclast precursors, which are subsequently
activated by RANKL and M-CSF and attach to the bone surface.
Resorption then begins, with osteoclasts degrading the bone
and liberating growth factors trapped within the matrix before
undergoing apoptosis. Macrophages clear away the debris from
the resorption pit and a transition to the formation phases
begins. Initially, osteoid, a collagenous matrix, is deposited
to fill the cavity. This is mineralised over the following 3–6
months by osteoblasts secreting matrix vesicles that establish
an environment conducive to mineralisation by increasing
the concentration of calcium and phosphorous ions. During
this process, some osteoblasts become trapped and undergo
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FIGURE 2 | The RANKL/RANK/OPG axis and M-CSF direct osteoclastogenesis and activation.
FIGURE 3 | The five stages of bone remodelling.
osteocytogenesis whilst others undergo apoptosis or become
bone lining cells (Dempster, 2006; Kini and Nandeesh, 2012).
For remodelling to be successful, it is imperative that
the existing bone matrix is completely removed prior to
the formation of new bone. However, very few collagenases
can degrade the fibrillar collagen type 1 found within bone;
the most notable exceptions are cathepsin K and matrix
metalloproteinase-9 (MMP-9). This difficulty arises from the
tightly packed, helical structure of the collagen and surrounding
minerals making it inaccessible (Sprangers and Everts, 2017). To
overcome this, osteoclasts bind to the bone surface and form
a sealed zone through cytoskeleton rearrangement to form a
ring of actin. Within this ring the plasma membrane enlarges
and becomes convoluted forming a ruﬄed membrane with
finger-like projections to increase surface area and therefore
contact with the bone matrix. This compartment is acidified
to demineralise the bone matrix, exposing fibrillar collagen
within.
This low pH zone also provides the optimal conditions for
cathepsin K, a lysosomal cysteine protease secreted through the
ruﬄed border, to degrade the collagenous matrix (Teitelbaum,
2000). The serum concentration of the degradation products
of cathepsin K, the carboxy- and amino-terminal telopeptides
of collagen type 1 (CTX and NTX, respectively), can be
used as markers of bone turnover (Garnero et al., 2003).
Similarly in vitro, their concentration in culture media can
be determined by ELISA as evidence of collagen degradation.
MMP-9 is the most expressed MMP by osteoclasts and is
also capable of degrading demineralised collagen. However,
in addition to this role it also appears to be involved in
osteoclast recruitment through the conversion of the inactive
form of TNF-α into the active cytokine, promoting osteoclast
formation and survival. An extensive review by Paiva and
Granjeiro explores the roles of the MMP family in bone
(Paiva and Granjeiro, 2017).
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Metabolic Bone Diseases
Metabolic bone diseases, such as osteoporosis, osteopetrosis
and rickets, affect the bone remodelling process. They can
alter bone balance both positively and negatively, resulting in
either excessive bone formation or bone resorption, respectively.
Osteopetrosis is a metabolic bone disease that causes a positive
bone balance. It is a rare (1 in 20,000 to 250,000 depending
on type) inherited disorder that results in increased bone mass
and BMD caused by a dysfunction in the ability of an osteoclast
to acidify its resorption pit, resulting in improper resorption
(Sobacchi et al., 2013). This impaired resorption combined with
continued bone formation results in denser, more brittle bones
that are more susceptible to fracture (Tolar et al., 2004; Stark and
Savarirayan, 2009).
Rickets is caused by a vitamin D deficiency that inhibits
osteoblast progenitors and increases RANKL whilst decreasing
OPG expression, resulting in increased bone resorption and
turnover (Lips et al., 2013). Multiple myeloma, a cancer of
plasma cells, can also cause severe bone destruction through
a remodelling imbalance. The hallmark osteolytic lesions form
in close proximity to myeloma cells due to hyperactivity of
osteoclasts and hypoactivity of osteoblasts (Giuliani et al., 2014).
The most prevalent metabolic bone disorders are osteopenia
and osteoporosis, both of which describe a loss of bone mineral
density (BMD). TheWorld Health Organisation states that when
a patient’s BMD falls between 1 and 2.5 standard deviations
below that of a healthy young adult they are classed as osteopenic,
lower than−2.5 is diagnosed as osteoporotic (National Institutes
of Health, 2000). Osteoporosis refers to a group of conditions,
rather than a specific, single entity. It is classified as primary type
1, primary type 2 or secondary. Type 1 is the most common
and is often referred to as postmenopausal osteoporosis as it
is caused by an associated oestrogen deficiency that results in
increased RANKL and decreased OPG production and reduced
osteoclast apoptosis (Saika et al., 2001; Eghbali-fatourechi et al.,
2003; Nakamura et al., 2007). Type II is also known as senile
or age-related osteoporosis and can occur in both men and
women with age. Finally, secondary osteoporosis refers to
when the disorder is present as a consequence of an adverse
response to a medication, change in physical activity, or another
medical condition. Common examples of this type include
glucocorticoid- and immobilisation-induced osteoporosis
(Feng and McDonald, 2011), as well as inflammation-induced
bone loss as the result of overexpression of RANKL by
immune cells during periodontitis or rheumatoid arthritis
(Schett and David, 2010; Redlich and Smolen, 2012).
Osteoporosis reduces bone strength through a reduction in
mass and deterioration of the microarchitecture, resulting in an
increase in fragility and an increased susceptibility to fracture
(Raisz, 2005). Currently, 50% of women and 20% of men over
the age of fifty will have a fragility fracture, and there are an
estimated 158 million people over the age of 50 at high risk of
osteoporotic fracture worldwide, with this predicted to double by
2040 (Odén et al., 2015). In 2010, the financial burden of treating
osteoporotic fractures in the UK and Germany was estimated to
be e5.5 billion and e9.1 billion, respectively (Ström et al., 2011).
However, the demographics of western countries are changing
with an increasing proportion of the population exceeding 50
years of age, thus further increasing the incidence and cost each
year (Egermann et al., 2005). For example, the financial burden
in Canada was estimated to be $2.3 billion in 2008, but this was
revised to $4.6 billion in 2016 (Hopkins et al., 2016).
The Need for in vitro Models
In 2015, 2.08 million experimental procedures were performed
on animals in the United Kingdom. 1.1 million were for basic
research purposes, with 25,381 of these within the field of
musculoskeletal research. 89% of these studies were conducted on
mice and rats (Home Office UK, 2015). The popularity of rodent
models for bone disorders arises from a relatively minimal public
opposition to their use, as well as low cost and ease of housing
in comparison to other, larger animal alternatives (Bonucci and
Ballanti, 2013). Furthermore, their size makes them amenable to
non-invasive, high resolution in vivo imaging techniques such as
micro-CT (van der Linden et al., 2006; Dall’Ara et al., 2016) and
the application of mechanical loading in vivo (Gross et al., 2002).
However, despite becoming a fundamental component of pre-
clinical research, mouse physiology does not accurately represent
the human condition, with many aspects of human anatomy
not well represented in a murine model. This is demonstrated
by the poor translation of pre-clinical efficacy in animal models
to human clinical trials and the vast majority of promising
discoveries failing to enter routine clinical use (Burkhardt and
Zlotnik, 2013; Mcgonigle and Ruggeri, 2013; Benam et al., 2015;
Malfait and Little, 2015).
Although in vivo models are viewed as the gold standard for
studying diseases and testing new therapies, their use should
align with the philosophy of the 3Rs – reducing, refining and
replacing animal testing (Peric et al., 2015). In addition to
these principles, in September 2010 the EU Directive “Directive
2010/63/EU—Legislation for the protection of animals used for
scientific purposes” was adopted for research in EU nations.
This supports the principles of the 3Rs, widening their scope
and laying down standards for housing and care of animals.
Furthermore, it aims establishes a Union reference laboratory
for the validation of alternatives to animal models in order
to promote their development, validation and implementation
(European Union, 2010). These limitations of in vivo models
give rise to the development of in vitro alternatives. However,
the clinical relevance of these systems should be interpreted with
caution as they lack the complexity of in vivo physiology. Despite
this, if aspects of preclinical testing can be replicated or improved
on in vitro before proceeding to in vivo then the use of some
animals can be reduced.
Types of in vitro Model
Even the most minimal in vitro models of bone remodelling
fundamentally require the co-culture of osteoblasts and
osteoclasts. However, these can be performed either indirectly
or directly. Indirect methods include conditioned media and the
use of transwell inserts. The former takes media from one cell
type and adds it to another, whereas the latter uses a permeable
insert to provide two culture surfaces in the same well, allowing
exchange of soluble factors but no cell-cell contact between the
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FIGURE 4 | Different methods of co-culturing cells. Conditioned media
transfers media used in one culture to another. Well inserts culture cells in the
same well but only soluble factors can exchange between cell types. Direct
co-cultures can be performed in 2D or 3D and permit membrane bound and
soluble factors to exert influence.
two types. Direct methods co-culture both cell types on the same
surface, be it a planar, two-dimensional (2D) tissue culture well
or a three-dimensional scaffold (Figure 4). This approach allows
for immediate physical contact between the cells types, meaning
that the effects of membrane-bound signalling molecules can be
explored as well as soluble factors.
A recent review suggested that when testing bone implant
and repair materials in vitro, overlooking bone remodelling is
a key limitation of the approaches currently taken (Kohli et al.,
2018). That paper makes a strong case for improving our ability
to replicate this process for in vitro biomaterial testing; therefore,
biomaterials testing is not discussed in this review. Rather, the
current review summarises the key research that has been done
thus far in creating an in vitro model of bone remodelling,
focussing on fundamentals, 3Dmodels of the process, and disease
orientated-models.
We searched in PubMed for “in vitro AND osteoblast AND
osteoclast AND (co-culture OR co culture) AND remodelling,”
limiting results to relevant original research articles written in
English. The resulting papers were divided into three categories:
modulators of remodelling; which explores which factors can
affect the remodelling process, remodelling models; which
attempt to mimic the process in vitro as a tool for understanding
physiology or drug/material testing, and disease-orientated
models; that introduce additional cells or factors (e.g., cancer
cells or inflammatory molecules) to the osteoblast-osteoclast co-
culture to investigate their effects on remodelling. Common
osteoclastic and osteoblastic cell types used are summarised
in Tables 1, 2, and proteins, genes and molecules referred to
throughout this review are listed in Table 3.
MODULATORS OF REMODELLING
Since the 1980s it has been known that osteoblast-lineage
cells release factors that stimulate osteoclastic resorption, and
in vitro experiments were essential in their elucidation. For
example, the discovery of interleukin-6 and M-CSF, as well as
TABLE 1 | Common osteoclastic lineage cell types used in vitro.
Name Abbreviation Description
Peripheral Blood
Mononuclear Cell
PBMC Mononuclear cells (predominantly
lymphocytes and monocytes) isolated
from peripheral blood or buffy coats,
typically via density gradient centrifugation
(Henriksen et al., 2012).
Monocyte MNC Monocytes (osteoclast precursors) can be
further isolated from PBMCs, for example
by negative selection using
magnetic-activated cell sorting or
adhesion-selection. Their purity can be
confirmed by flow cytometry using
antibodies against CD14 and CD45
(Domaschke et al., 2006; Anaraki et al.,
2015).
Bone marrow
derived precursors
– Bone marrow consists of haematopoietic
tissue and the supporting stroma.
Non-adherent cells within the former can
be isolated and differentiated into
osteoclasts (Gori et al., 2000; Lindner
et al., 2010).
RAW264.7
(ATCC®
TIB-71TM)
RAW264.7 Murine leukemic monocyte macrophage
cell line that can undergo osteoclastic
differentiation by RANKL exposure. A key
advantage over other precursors is that
they do not require co-stimulation with
M-CSF (Collin-Osdoby et al., 2003; Zhang
et al., 2012).
THP-1 THP-1 Human monocytic cell line derived from
the blood of a boy with acute monocytic
leukaemia (Tsuchiya et al., 1980).
the RANKL/RANK/OPG axis that mediates osteoclast formation
and function (McSheehy and Chambers, 1986; Ishimi et al., 1990;
Greenfield et al., 1992; Jimi et al., 1996; Pacifici, 1996; Feng
and McDonald, 2011). M-CSF and RANKL can be produced as
either membrane bound (mM-CSF/mRANKL) and/or secreted,
soluble forms (sM-CSF/sRANKL). Factors that can modulate
the expression of M-CSF, RANKL and OPG can direct whether
bone remodelling has a negative, neutral or positive balance,
controlling whether bone tissue is lost or gained.
Throughout this review a range of culture media is used
depending on the cell type(s) being grown. Due to the range
of studies discussed, the exact formulation cannot be detailed
each time. However, osteogenic medium for the growth and
differentiation of osteoblasts typically refers to a culture medium
supplemented with dexamethasone, β-glycerolphosphate (βGP)
and ascorbic acid, although the concentration of each varies
between research groups. A comprehensive review of their
roles is given by Langenbach and Handschel; but to summarise
briefly, dexamethasone is a glucocorticoid that upregulates
osteogenic differentiation, βGP acts as a phosphate source for
the production of hydroxyapatite and ascorbic acid is a co-
factor for enzymes involved in collagen synthesis (Langenbach
and Handschel, 2013). Although these supplements are added
to permit osteoblast differentiation and function, they have each
been associated with enhanced osteoclast formation (Kaji et al.,
1997; Takuma et al., 2003; Le Nihouannen et al., 2010; Noh
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TABLE 2 | Common osteoblastic lineage cell types used in vitro.
Name Abbreviation Description
Primary
Osteoblast
- Osteoblast-like cells extracted from
primary bone. Human osteoblasts are
typically from trabecular bone fragments
(Tanaka et al., 2000; Xie et al., 2012),
murine osteoblasts from calvaria (Tortelli
et al., 2009; Vinik et al., 2015).
Mesenchymal
stem cell
MSC Bone marrow consists of haematopoietic
tissue and the supporting stroma. A
subpopulation of adherent stromal cells
within the latter have multipotent
differentiation capacity (e.g., osteoblasts,
chondrocytes, adipocytes) and are
commonly referred to as mesenchymal
stem cells. Similar cells have also been
derived from other tissues (e.g., adipose
and umbilical cord) (Lindner et al., 2010).
Immortalised
osteoblast
precursors from
human bone
marrow stroma
hMS(2-15) Osteoblast precursor cell line developed
from human bone marrow stromal fraction
(Hicok et al., 1998).
ST-2 ST-2 Clone of murine stromal cells isolated from
BC8 mice that develop an osteoblastic
phenotype when cultured with ascorbic
acid (Otsuka et al., 1999).
MC3T3-E1 MC3T3-E1 Spontaneously immortalised clonal
osteoblast precursor cell line generated
using the 3T3 passaging protocol from the
calvaria of newborn C57BL/6 mice by
Kodama et al. (1981).
Human
periodontal
ligament cells
(between alveolar
bone and the
tooth root)
PDL Osteoprogenitor cells of periodontal
ligament connective tissue (Basdra and
Komposch, 1997; Chou et al., 2002).
MLO-Y4 MLO-Y4 Osteocyte cell line cloned from cells
isolated from murine long bones (Kato
et al., 1997).
and Yim, 2011). Osteoclastogenic medium typically refers to
culture medium supplemented with RANKL and M-CSF. Where
other, non-standard factors are added to the medium, e.g.,
vitamin D or parathyroid hormone, these are mentioned in the
text.
The RANKL:OPG Ratio Changes With
Progression Through the Osteoblast
Lineage
Although RANKL and OPG are produced by cells of the
osteoblastic lineage, their expression varies depending on the
progression of their differentiation from precursor to osteocyte.
Culture of hMS(2-15) immortalised osteoblast precursors in
osteogenic medium over 21 days sees an increase in ALP
activity and mineralised matrix production over time. During
this period, RANKL mRNA levels reduce and OPG mRNA levels
are elevated in comparison to cultures in basal media, reducing
TABLE 3 | Common factors analysed during in vitro bone cultures.
Name Abbreviation Description
Receptor activator
of nuclear factor κβ
RANK Receptor for RANKL expressed on
osteoclast-lineage cells (Boyce and Xing,
2007).
Receptor activator
of nuclear factor κβ
ligand
RANKL Member of tumour necrosis factor cytokine
family. Ligand for RANK receptor
predominantly produced by
osteoblast-lineage cells, but also by stromal
and T cells (Boyce and Xing, 2007).
Osteoprotegerin OPG Decoy receptor that prevents RANK
activation by binding with RANKL (Boyce
and Xing, 2007).
Macrophage colony
stimulating factor
M-CSF Cytokine that influences differentiation and
survival of haematopoietic precursors,
produced by osteoblasts and stromal cells
(Hodge et al., 2007).
Alkaline
phosphatase
ALP Enzyme secreted from osteoblasts which
promotes hydroxyapatite crystal formation
within the bone matrix. Considered a highly
specific marker of bone-forming
osteoblasts (Orimo, 2010).
Collagen type 1 COL-1 Protein that constitutes ∼90% of the
organic phase of bone (Farbod and
Nejadnik, 2013).
Runt-related
transcription
factor 2
RUNX2 Key transcription factor associated with
osteoblast differentiation (Komori, 2010).
Osterix OSX Transcription factor also known as Sp7
required for bone formation, works
downstream of RUNX2 (Nakashima et al.,
2002).
Osteopontin OPN OPN is an extracellular matrix glycoprotein.
During remodelling, it anchors osteoclasts
to the bone matrix (Reinholt et al., 1990).
Integrin binding
sialoprotein/Bone
sialoprotein-2
IBSP/BSP-II Human variant of BSP, significant
component of bone extracellular matrix
(Fisher et al., 1990).
Tartrate-resistant
acid phosphatase
TRAP Enzyme secreted by osteoclasts. Activity
strongly correlates with bone resorption
and TRAP knockout mice develop
osteopetrosis (Hayman et al., 1996).
Cathepsin K CTSK Osteoclastic cysteine protease that
catabolises bone by breaking down
collagen (Sprangers and Everts, 2017).
Matrix
metalloproteinase-9
MMP-9 Osteoclastic enzyme that degrades
extracellular matrix components such as
collagen and gelatin (denatured collagen)
(Sprangers and Everts, 2017).
Osteoclast
associated receptor
OSCAR An IgG-like receptor that is an important
osteoimmunological mediator and acts as a
co-stimulatory receptor for osteoclast
differentiation (Nemeth et al., 2011).
Parathyroid
hormone
PTH A hormone that can indirectly stimulate
osteoclastogenesis by action on
osteoblasts. Depending on concentration
and frequency of application, it can have a
catabolic or anabolic effect (Borba and
Mañas, 2010).
1α,25(OH)2D3 Vitamin D3 1α,25-dihydroxyvitamin D3 is the active
form of vitamin D3. It has been shown to
stimulate RANKL expression in osteoblasts
and osteocytes (Kitazawa and Kitazawa,
2002; Shevde et al., 2002; You et al.,
2008).
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the RANKL:OPG ratio. The presence of undifferentiated
hMS(2-15) that have the greatest RANKL:OPG ratio results in
the differentiation of murine bone marrow-derived osteoclast
precursors into TRAP positive multinucleated osteoclasts in co-
culture, whilst differentiated cells did not induce differentiation
unless exogenous sRANKL was added (Gori et al., 2000).
However, the ability to generate osteoclasts does not
necessarily diminish as osteoblastic cells continue to differentiate.
Osteoblasts that terminally differentiate into osteocytes and
become embedded within the mineralised matrix of bone
also have the ability to modulate bone remodelling. MLO-Y4
osteocyte-like cells can induce the formation and activation
of osteoclasts capable of resorbing dentine in direct co-
culture with murine spleen or marrow cells without the
addition of any exogenous factors, although supplementation
with Vitamin D3 enhances their production. However, in an
indirect co-culture where conditioned media was taken from
an MLO-Y4 monoculture and added to an osteoclast precursor
monoculture, osteoclasts were not generated despite sM-CSF
being present. This indicates that M-CSF alone cannot induce
osteoclastogenesis, and that MLO-Y4 must stimulate osteoclast
formation through the mRANKL detected on their surface and
dendritic processes, meaning that direct cell contact is required
in this culture system (Zhao et al., 2002).
Mechanical forces sensed and transduced at the cellular level
can also affect the RANKL:OPG ratio. Thismechanotransduction
can occur through either fluid shear stress (FSS) via the
primary cilium, glycocalyx or ion channels, or matrix strain via
integrins (Wittkowske et al., 2016). It is thought that osteocytes
inhibit bone resorption in areas of high mechanical loading by
downregulating RANKL and upregulating OPG in response to
changes in fluid flow that occur within the tissue. Kulkarni,
et al., applied pulsatile fluid flow (PFF) to MLO-Y4, finding
that this inhibited their ability to induce osteoclastogenesis
in murine bone marrow cells by decreasing the RANKL:OPG
ratio (Kulkarni et al., 2010). Kim, et al., also investigated
the effect of fluid flow on RANKL and OPG expression by
applying oscillating fluid flow (OFF) to ST-2 stromal cells
before initiating a direct co-culture with RAW264.7 monocyte
macrophages. OFF reduced the RANKL:OPG ratio by lowering
RANKL and stimulating OPG mRNA expression, resulting in
fewer osteoclasts being formed in comparison to a static control
(Kim et al., 2006).
Direct matrix strain can also affect the RANKL:OPG ratio.
Using a transwell co-culture system where RAW264.7 were
cultured on a membrane above mechanically strained MC3T3-
E1 osteoblast precursors, Zhang et al. found that loading of
the osteoblasts resulted in higher ALP activity and lowered
osteoclast activity, as demonstrated by a decline in TRAP activity,
resorption, CTSK and MMP-9 expression, in comparison to
static controls. This was due to a lower RANKL:OPG ratio by
reduced OPG expression (Zhang et al., 2013). Unlike with MLO-
Y4 co-cultures, in this culture system, direct contact between
osteoblast- and osteoclast-lineage cells was not necessary to
induce osteoclastogenesis. This highlights how although RANKL
can exist in both membrane-bound and soluble isoforms, both
types are not necessarily present in sufficient concentrations to
induce osteoclast differentiation in all osteoblast sources and
culture conditions.
To investigate how osteocytes may regulate osteoclast activity,
Gu et al. cultured primary rat osteoclasts on rat calvaria slices
that had been stripped of the periosteum and endosteum to
leave predominantly osteocytes in the samples. These were
either cultured to maintain living cells or devitalised using
water and sonication or freeze-thawing. Cultures on devitalised
bone produced significantly more and deeper resorption pits in
comparison to living bone, and conditioned media from living
bone samples inhibited osteoclast resorption, indicating the
live osteocytes were preventing resorption. Inducing osteocyte
apoptosis via glucocorticoid application prior to osteoclast
culture greater resorption in comparison to untreated calvaria
(Gu et al., 2005). The alteration of this ratio over time may
help co-ordinate the osteoblasts and osteoclasts during the
remodelling cycle.
When considered in the context of remodelling and bone
homeostasis in vivo, the need for the osteoclastogenic potential
of osteoblast-lineage cells to change as they progress from
mesenchymal stem cells (MSC) to osteoblast to osteocyte is clear.
During the initial stages of remodelling when osteoblast and
osteoclast precursor cells are being recruited from the circulatory
system, monocytes need to differentiate into mature osteoclasts
so that the cutting cone of the BMU can develop and resorb
the bone tissue; therefore, a RANKL:OPG ratio that promotes
osteoclast formation is necessary. However, once osteoblasts are
synthesising new osteoid, osteoclastogenesis is not desirable as it
could result in the resorption of the newly formed bone tissue;
hence the reduction in the RANKL:OPG ratio. Once terminally
differentiated into osteocytes, it is important that bone strength
is preserved. Therefore, it is predicted that in loaded regions
of bones osteocytes have a low RANKL:OPG ratio to minimise
resorption, whereas in unloaded or damaged areas of bone,
the RANKL:OPG of the osteocytes is higher to promote bone
remodelling.
Other Proteins and Hormones That can
Modulate the RANKL:OPG Ratio
There are a wide range of factors which can modulate the
RANKL:OPG ratio and therefore osteoclastogenesis and bone
remodelling. Retinoids are important for normal bone growth
and development. Geranylgeranoic acid (GGA), a synthetic
acyclic retinoid, can promote a positive bone balance through
a dual action of stimulating osteoblast differentiation and
inhibition of osteoclast formation, as demonstrated by Wang,
et al., who found it suppressed MC3T3-E1 proliferation whilst
increasing ALP activity, reduced osteoclast formation in co-
cultures of murine bone marrow cells and osteoblasts, and
upregulated OPG mRNA expression in ST-2 cells after it had
been chemically supressed. Furthermore, it inhibited osteoclast
formation in sRANKL and sM-CSF treated bone marrow
cultures, indicating it can act on both osteoblasts and osteoclasts
(Wang et al., 2002).
Hydrolysed collagens have also been shown to promote a
positive bone balance in vitro, with 2 kDa hydrolysed collagen
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molecules increasing ALP activity and decreasing resorption in
co-cultures of primary murine osteoblasts and bone marrow
cells (Guillerminet et al., 2010). The presence of omentin-1,
an adipokine also known as intelectin-1, reduces the number
of TRAP positive, multinucleated osteoclasts in co-cultures of
human osteoblasts and monocytes (MNCs) and well as MC3T3-
E1 and RAW264.7 through stimulation of OPG and inhibition
of RANKL protein expression (Xie et al., 2012). Lactoferrin is a
glycoprotein that has an anabolic effect on bone by promoting
osteoblast proliferation and differentiation as well as decreasing
osteoclast formation (Lorget et al., 2002; Zhang et al., 2014).
By coupling it to hydroxyapatite nanocrystals, Montesi et al.
showed that these two compounds can synergistically act as a
bone anabolic by increasing OSX and IBSP mRNA expression in
osteoblasts, reducing osteoclast formation, and downregulating
OSCAR and CTSK mRNA expression in co-cultures of MC3T3-
E1 and RAW264.7 (Montesi et al., 2015).
Galectins are glycan-binding proteins that can link ECM
components and cell-surface receptors. Vinik et al. investigated
how galectin-8 (GAL-8) can regulate RANKL production by co-
culturing murine osteoblasts with murine bone marrow cells
and treating with GAL-8. They found that GAL-8 can bind to
the LRP1, MRC2, and uPAR receptors and stimulate a six-fold
increase in RANKL mRNA expression and a 2.5-fold increase in
sRANKL production whilst reducing OPG expression by 30%,
resulting in a 15-fold increase in TRAP positive, multinucleated
osteoclast generation. Furthermore, osteocytes extracted from
the same calvaria treated with GAL-8 also had higher RANKL
expression (Vinik et al., 2015).
Glycosaminoglycans (GAGs) are found in the ECM of bone
and have been used in biomaterial applications to stimulate
osteogenesis. Salbach-Hirsch et al. used GAGs and sulphated-
GAGs (sGAGs) to create artificial ECMs for culturing RAW264.7
in the conditioned media of murine osteoblasts generated from
MSCs. They found that sGAG matrices significantly increased
ALP, osteocalcin and OPG expression as well as mineralized
matrix deposition. However, supernatants could not induce
osteoclast formation due to the absence of sRANKL and the
high level of OPG. Addition of exogenous sRANKL permitted
osteoclast formation, but the lowest levels of differentiation and
resorption were seen in the sGAG groups due to the greater OPG
production, indicating that GAGs can have an anabolic effect on
bone through action on the osteoblasts (Salbach-Hirsch et al.,
2014).
Parathyroid hormone (PTH) plays a major role in calcium
and phosphate homeostasis (Figure 5). When this feedback loop
is disrupted, for example when PTH is continuously produced
in hyperthyroidism, there is a catabolic effect on bone. This is
partly the result of the inhibition of expression and synthesis of
ECMproteins, such as collagen I, osteocalcin, and ALP. However,
despite this reduced matrix formation, PTHmediated catabolism
of bone is not primarily due to diminished osteoblast function,
but elevated osteoclast function. The prevailing scientific opinion
is that only osteoblast-lineage cells possess a PTH receptor, with
only a small number of researchers reporting that they are
also present on osteoclast-lineage cells. Therefore, this raised
osteoclast activity is not through direct action of PTH, but rather
FIGURE 5 | The calcium, PTH, Vitamin D3 homeostatic feedback loop.
an indirect response to altered osteoblast function as continuous
PTH raises RANKL and lowers OPG expression, increasing the
RANKL:OPG ratio (Dempster et al., 2005; O’Brien et al., 2008;
Silva and Bilezikian, 2015; Liu et al., 2016).
In contrast to the loss of bone observed when PTH is
continuously applied, intermittent application of exogenous
PTH, for example the application of teriparatide in the treatment
of osteoporosis, can have an anabolic effect on bone by increasing
formation in both cancellous and cortical regions (Figure 6). This
is because intermittent administration stimulates bone formation
by promoting bone-lining cell activation andMSC differentiation
to osteoblasts, inhibiting sclerostin in osteocytes, and increasing
osteoblast lifespan by inhibiting apoptosis (Lindsay et al., 1997;
Kousteni and Bilezikian, 2008; Borba and Mañas, 2010; Silva
and Bilezikian, 2015). Although this can seem paradoxical, the
anabolic effect is due to the immediate response of osteoblasts
in contrast to the delayed secondary response of osteoclasts
after administration. This differential gives rise to an “anabolic
window,” where there is an initial stimulation of formation
without resorption (bone modelling) followed by a later increase
in overall bone turnover (bone remodelling). After each PTH
cycle there is a net increase of high quality bone similar to that
of younger individuals, predominantly at regions subjected to
mechanical stress; hence its potency as an osteoporosis treatment
(Bodenner et al., 2007; Silva and Bilezikian, 2015).
Osteoclastogenesis and bone resorption can also be affected
by modulating the expression of or by knocking out (KO)
proteins involved in the signalling pathways downstream from
cell surface receptors. This can be done directly in osteoclasts
or indirectly by affecting the RANKL:OPG ratio in osteoblasts.
Although altering these signalling cascades is a potent method
of modifying remodelling, as these pathways are not specific to
the process being examined its use as a potential therapeutic
should be treated with caution. Below are two examples of how
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FIGURE 6 | The anabolic or catabolic effects of PTH on bone depends on application modality.
knocking out proteins in these signalling pathways can affect
osteoclastogenesis. As the intricacies of how these pathways
function is outside the scope of this review, only a brief
explanation of their function is given here.
β-arrestin2 is an adaptor/scaffold protein that can regulate
intracellular signalling initiated by the PTH-receptor, when β-
arrestin2 KO vs. wild-type (WT) bone marrow cultures are
compared, enhanced osteoclastogenesis is seen in the KO
phenotype due to a higher RANKL:OPG ratio (Pierroz et al.,
2009). Lossdörfer et al. co cultured periodontal ligament (PDL)
cells with RAW264.7 in the presence of intermittent PTH, finding
that the response depends on thematurity of the PDL cells.When
applied to co-cultures containing mature, confluent PDL cells,
an upregulation of TRAP and CTSK expression and an increase
in the RANKL:OPG ratio and resorptive activity was observed;
however, in less mature, pre-confluent cells the opposite was seen
with downregulation of resorptive genes, and a decrease in the
ratio and amount of resorption. Similar results were seen when
treating RAW264.7 with conditioned media from the PDL cells,
indicating the PDL cells can produce sRANKL and their response
to PTH is dependent on cell maturity (Lossdörfer et al., 2011).
Downstream of tyrosine kinase (DOK) 3 protein is an
adapter protein that limits tyrosine kinase-mediated signalling
downstream of cell surface receptors such as c-fms on osteoclasts
(Mashima et al., 2009). Cai et al. found that DOK3 KO mice
are osteoporotic due to a higher number of TRAP positive
osteoclasts. In vitro, osteoclasts differentiated from KO bone
marrow had heightened sensitivity to RANKL resulting in
amplified osteoclastogenesis, larger osteoclasts with more nuclei
and enhanced resorptive capability. Osteoblasts derived from
DOK3 KO mice produce less mineralised matrix and reduced
expression of RUNX2, OSX, COL-1, and ALP mRNA, as
well as reduced RANKL and increased OPG expression in
comparison to WT. In direct co-culture, WT osteoblasts induced
more osteoclasts from KO precursors than WT precursors and
KO osteoblasts induced fewer osteoclasts from KO and WT
precursors that WT osteoblasts, indicating that DOK3 promotes
osteoblastogenesis and impedes osteoclastogenesis (Cai et al.,
2017).
The Influence of Culture Media
Serum, typically foetal bovine serum, is added to culture media
as it contains a variety of proteins that help cells grow, divide
and survive. However, its composition is not fully defined and
therefore varies between batches (Baker, 2016). This can give rise
to inconsistencies in results due to the influence of unknown
factors in the medium. Atkins et al. attempted to develop a
human-derived co-culture in a defined serum-free medium.
They found that in serum-replete medium, ST-2 osteoblasts
supported the formation of osteoclasts from human peripheral
blood mononuclear cells (PBMCs) in co-culture. However,
when the ST-2 cells were replaced with human osteoblasts,
osteoclast formation ceased. When repeated in a defined, serum-
free medium, co-culture of human osteoblasts with osteoclast
precursors resulted in functional osteoclast formation, indicating
some factor may have been present in the serum that inhibited
osteoclastogenesis (Atkins et al., 2005).
The concentration of calcium and phosphate in the media can
also affect osteoclastogenesis. Co-culture of MC3T3-E1 murine
pre-osteoblasts with murine bone marrow cells on segments of
bovine tooth-roots with calcium concentrations ranging from
0 to 2.5mM found increased TRAP staining and resorption
with lower calcium (Shirai et al., 1999). The same group found
that as MC3T3-E1 ALP activity and therefore extracellular
inorganic phosphate increases over time there is diminished
osteoclast formation, and that increasing concentrations of
β-glycerophosphate (βGP) and exogenous ALP in the media has
a similar effect (Takeyama et al., 2001).
Environmental Factors
In addition to chemical stimulus, environmental factors can
also mediate osteoclastogenesis. Dandajena et al. indirectly co-
cultured human osteoblasts with human PBMCs using well
inserts in either normoxic (21% O2) or hypoxic (2.5% O2)
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conditions, finding that low oxygen significantly upregulated
RANKL production in comparison to normoxia, and that TRAP
positive, resorptive osteoclasts only formed in hypoxic co-
cultures (Dandajena et al., 2012).
The Effect of Osteoclasts on Osteoblasts
Although the relationship between osteoblasts and osteoclasts
is perhaps often considered to be one-sided, with the former
producing factors that modulate the latter’s behaviour, there is
increasing evidence that osteoclasts can also affect osteoblasts.
This has seen a shift in thinking from the assumption that the
osteoclast is a single-function cell type that destroys the tissue it
resides in to understanding that it has additional regulatory roles
in bone remodelling (Cappariello et al., 2014).
Garimella et al. co-cultured primary murine calvarial
osteoblasts with murine bone marrow cells to generate TRAP
positive, multinucleated osteoclasts. Using in situ hybridisation
and immunohistochemistry they were able to detect bone
morphogenetic protein (BMP)-2, -4, and -6 mRNA and protein,
respectively, within the osteoclasts. RT-PCR confirmed that the
osteoclasts could synthesise mRNAs for BMP-2, -4, -6, and -
7, with BMP-6 having the highest expression (Garimella et al.,
2008). Osteoclastic BMPs are possibly involved in the initiation
of the anabolic phase of remodelling, recruiting, and activating
osteoprogenitor cells (Pederson et al., 2008). Further evidence for
the influence of osteoclasts on osteoblasts comes from Luo et al.
who also co-cultured primary murine calvarial osteoblasts with
murine bone marrow cells, albeit in a transwell configuration
resulting in no direct osteoblast-osteoclast contact. Their findings
demonstrated greater ALP staining and activity in osteoblasts
co-cultured with osteoclasts in comparison to monocultures.
Furthermore, the osteogenesis related genes RUNX2, ALP, and
COL-1 mRNA expression were all upregulated in the co-culture,
indicating the anabolic role osteoclasts can have on osteoblasts
(Luo et al., 2016).
REMODELLING MODELS
Much of the work done on the fundamentals of bone remodelling
in vitro has been performed using either (1) conditioned
media experiments, (2) indirect co-culture using well inserts
that keep the osteoblasts and osteoclasts separate, or (3) in
direct co-culture, where osteoclasts are plated onto a monolayer
of osteoblasts grown on tissue culture plastic. Whilst these
studies have revealed a plethora of factors and molecules
involved in remodelling, they fail to replicate the 3D architecture
of native bone tissue. This results in differences in cell
morphology, polarity and receptor expression, as well as a lack of
diffusion gradients and unrepresentative substrate stiffness that
in combination fail to represent the in vivo condition (Baker and
Chen, 2012). Therefore, to produce a viable model of remodelling
in vitro, the co-culture should be performed in three dimensions.
The development of the field of bone tissue engineering has
resulted in a multitude of polymer, ceramic and metal scaffolds
being produced that support the formation of mineralised ECM
(Bose et al., 2012; Owen et al., 2015). Those studies primarily
focus on the action of osteoblasts but such scaffolds can be
adapted to create in vitromodels of remodelling.
Nakagawa et al. appear to be the first to attempt to co-culture
osteoblasts and osteoclasts in a scaffold in vitro. Collagen-coated
porous PLGA scaffolds were precultured with porcine osteoblasts
for 2 weeks before the addition of porcine osteoclast precursors
and a further 2 weeks of culture in a rotational bioreactor. At
the end of the culture, mature osteoclasts with ruﬄed borders
and actin rings were visible on top of the mineralised surface
synthesised by the osteoblasts, showing for the first time that
studying remodelling in vitro is a realistic ambition (Nakagawa
et al., 2004).
Domaschke et al. were the first to demonstrate remodelling
in vitro and recognise its potential to reduce the need for
animal studies. Human MNCs were cultured on mineralised
collagen tapes containing hydroxyapatite for 24 h before the
addition of ST-2 and cultured in media supplemented with
exogenous RANKL and M-CSF. Osteoclasts generated were able
to resorb the scaffold-substrate and osteoblasts were able to
deposit new mineralised matrix, a key element that distinguishes
remodelling from resorption (Domaschke et al., 2006). Further
work by Bernhardt et al. utilised the same substrate but replaced
the murine ST-2 cells with primary human MSCs. However,
here osteoblasts were seeded on one set of scaffolds and
monocytes on another and kept separate from each other using
well inserts. Osteoblasts proliferated at a faster rate and ALP
mRNA expression was higher in co-culture than monoculture.
TRAP activity was lower on scaffolds and osteoclasts were
smaller in size in the co-culture in comparison to monocyte
monocultures. However, there was no difference in CTSK and
TRAP mRNA expression. Interestingly, across multiple donors
MSCs underwent less adipogenic differentiation in co-culture
than in monoculture, as evidenced by fatty acid binding protein
4 expression and Oil Red O staining (Bernhardt et al., 2010). This
indicates that without direct contact the presence of osteoblasts
can have an inhibitory effect on osteoclasts, perhaps via the
higher concentration of extracellular phosphate in the media
due to the presence of ALP as seen by Takeyama et al. (2001).
Furthermore, the presence of osteoclasts in indirect co-culture
upregulated the proliferation and ALP activity of osteoblasts and
inhibited adipogenesis, which agrees with the finding of Luo et al.
(2016).
Following the initial work of Domaschke, Tortelli et al.
developed an in vitro remodelling model using primary murine
cells. They used Skelite R©, a commercial bone graft substitute,
formed into discs to create a porous ceramic substrate and
compared it to TCP using co-cultures that were seeded in a
1:1 ratio of murine osteoblasts and osteoclast precursors from
murine bone marrow. These cultures were maintained for 30
or 60 days, 2–4 times longer than Domaschke et al. without
exogenous RANKL or M-CSF before analysis. Mature, TRAP
positive, multinucleated osteoclasts and deposited, mineralised
ECM were detectable after 60 days in 2D and 3D, with a more
organised bone-like matrix deposited in 3D. RUNX2, OSX, and
osteocalcin expression were analysed as markers of early, middle
and late osteoblast maturation and CTSK and TRAP expression
as markers of osteoclast differentiation. 3D cultures reached
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a maximal expression of RUNX2 and OSX within 10 days,
whereas 2D cultures took 40 days, and osteocalcin expression
was 19-fold higher in 3D by day 40, indicating osteogenesis
started immediately in 3D but was delayed in 2D, and that
osteoblasts fully differentiated in 3D. CTSK, TRAP, and RANKL
expression were significantly higher in 2D than 3D, whereas OPG
expression was lower (Tortelli et al., 2009). These results combine
to imply that osteoblasts in the earlier stages of osteoblastic
differentiation have higher osteoclastogenic potential that more
mature osteoblasts due to a greater RANKL:OPG ratio, and that
2D culture retains osteoblasts in an earlier phenotype due to a
lack of physical stimuli, which agrees with the findings on Gori
et al. (2000).
Although bone turnover at various time points can be
analysed by histology, PCR and enzyme activity, it is difficult
to determine exactly how a scaffold has been resorbed and
remodelled by the cells and impossible to see how bone tissue
volume on the same scaffold changes over time due to the
destructive nature of these techniques. Ruggiu et al. repeated the
same co-culture as Tortelli et al. on the same substrate but in
addition to histological techniques, examined the scaffold before
and after culture by x-ray computed microtomography (mCT)
using a synchrotron to enable image registration. In comparison
to murine OB monocultures, co-cultures formed a more
organised bone tissue with clear segregation between mineralised
ECM and non-mineralised osteoid. Using mCT, more extensive
mineralised and non-mineralised matrix deposition was seen
in co-cultures, as well as scaffold degradation due to osteoclast
activity which was not visible in murine OB monocultures
(Ruggiu et al., 2014).
The use of mCT as a non-invasive imaging technique to
monitor remodelling in vitro has also been utilised by Rubert
et al. who co-cultured human MSCs and MNCs on previously
mineralised and decellularised bone-like tissues in a spinner
flask for up to 35 days on media supplemented with RANKL
and M-CSF. By evaluating dynamic morphometric parameters
using sequential mCT scans, co-cultures had a significantly
decreased mineralising surface and almost 200% increase in bone
resorption rate in comparison to human MSC mono-cultures.
By registering images over time, regions of clear bone resorption
and formation could be seen in the co-culture (Figure 7) (Rubert
et al., 2017).
In addition to improving our understanding of the
remodelling process, in vitro systems can also inform us
how potential bone tissue engineering scaffolds will degrade and
be remodelled in vivo prior to animal testing. Jones et al. co-
cultured ofMC3T3-E1 and primary murine osteoclast precursors
on vapour or methanol stabilised silk fibroin, chitosan and PLLA
films to determine their suitability for bone tissue engineering.
Cultures were seeded at a 1:100 (OB:OC) ratio and maintained
in media containing exogenous RANKL for 10 days. Silk and
chitosan films supported the formation of superior numbers
of TRAP positive osteoclasts in comparison to PLLA, and by
comparing surface roughness using atomic force microscopy
(AFM), the most resorption occurred on vapour stabilised silk
films, indicating their potential for remodelling studies and use
in bone tissue engineering (Jones et al., 2009).
FIGURE 7 | (A) Day 21 and (B) day 35 mCT scans of human osteoblast and
osteoclast co-cultures registered to the original scaffold. Newly formed bone is
coloured orange, resorbed areas are blue, constant/quiescent areas are grey.
Adapted from (Rubert et al., 2017) under The Creative Commons
Attribution–ShareAlike License (CC-BY-SA).
Hayden et al. also utilised silk-based substrates in multiple
studies attempting to develop an in vitro bone remodelling
model. Initially they used lentiviral transduction to tether ligands
known to alter bone metabolism: either PTH or glucose-
dependent insulinotropic peptide (GIP), or a GFP control to
human MSCs differentiated into osteoblasts. These were co-
cultured with THP-1 monocytes in media with exogenous
RANKL on silk films, porous silk sponges or TCP for up
to 5 weeks before surface roughness and calcium deposition
quantification was performed to analyse resorption and matrix
deposition. Tethering of PTH increased mineral deposition
in comparison to the GFP control in 2D co-culture only,
possibly due to the feedback mechanism to the osteoblasts
from the more active osteoclasts. Greater surface roughness was
seen on silk films with PTH-tethered co-cultures due to the
production of larger mineral deposits, whilst GIP-tethered co-
cultures decreased roughness as GIP reduces osteoclasts activity
and therefore osteoclastic stimulation of matrix deposition by
osteoblasts. Similar surface roughness trends were seen in the
3D sponges, but due to their more complex architecture it is
harder to quantify (Hayden et al., 2014a). Following this, Hayden
et al. extended the duration of the co-culture with regular human
MSCs and THP-1 and exogenous RANKL on the silk films to
up to 32 weeks to characterise long term remodelling on the
substrate. Films were characterised by SEM and mCT imaging
prior to seeding. Mineralisation in co-culture in comparison
to monoculture was continuous over the surface of the film,
rather than in discrete patches. They also had higher surface
roughness indicating more remodelling and an increase in
volume as quantified bymCT (Hayden et al., 2014b). Finally, they
looked to apply their in vitro model to a metabolic bone disease
by investigating the effect of two bisphosphonates, a common
therapeutic for patients with osteoporosis. Here the silk films
were incorporated with hydroxyapatite and loaded with either
clodronate or alendronate before co-culture of human MSCs
and THP-1 with exogenous RANKL for up to 12 weeks. They
identified concentrations of clodronate that could upregulate
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osteoblast ALP activity whilst diminishing osteoclast activity,
a combination alendronate could not achieve (Hayden et al.,
2014c).
Heinemann et al. also developed an in vitro biomaterial testing
system that utilised an all-human origin, direct contact co-
culture that compared TCP with a silica-collagen-hydroxyapatite
xerogel (Heinemann et al., 2011). Human MSCs were cultured
for 13 days before the addition of human MNCs and further
culture for up to 4 weeks without exogenous RANKL or M-CSF.
Differentiation of MSCs into osteoblasts was confirmed by ALP
activity. RANKLwas synthesised as evidenced by RANKLmRNA
expression and TRAP activity of the differentiated osteoclasts,
which were also able to upregulate BSP-II gene expression in
osteoblasts. In 3D, MSCs proliferated and differentiated, forming
layers of cells that covered the entire sample which had spherical,
multinucleated osteoclasts with actin rings embedded within
(Figure 8).
A further in vitro bone model that only used human-
origin cells co-cultured in direct contact was developed by
Papadimitropoulos et al. However, in contrast to Heinemann,
they used human adipose tissue-derived stromal vascular fraction
(SVF) cells that can commit to osteoblastic and endothelial
lineages. These were co-cultured with human MNCs on porous
hydroxyapatite/β-tricalcium phosphate ceramic scaffolds in a
perfusion bioreactor, with the SVF cells cultured for 5 days
before the addition of the monocytes and the culture maintained
for 21 days in media supplemented with exogenous RANKL
and M-CSF. After 21 days, osteoblastic, osteoclastic, and
endothelial cells were identifiable in the culture, with TRAP
positive osteoclasts adhered to the deposited ECM. Culture
supernatants were analysed at multiple time points to assess
bone turnover, with increasing levels of C-terminus procollagen-
I (CICP) and decreasing phosphate concentrations indicating
matrix deposition, and increasing levels of N-telopeptides of
collagen type-I (NTX) and raised phosphate concentrations and
TRAP activity indicating matrix resorption (Figure 9). When
replacing exogenous supplementation of RANKL and M-CSF
with Vitamin D3 co-cultures still underwent osteoclastogenesis,
resulting in self-regulation of the model (Papadimitropoulos
et al., 2011). Sequentially monitoring key markers in the culture
supernatants to assess bone turnover is similar in principle
to the longitudinal imaging approaches performed by Ruggiu
et al. (2014) and Rubert et al. (2017). These non-invasive and
non-destructive techniques both allow the same culture to be
examined at multiple time points, reducing the total number
of cultures required. Ideally, these two approaches would be
combined, allowing both the amount and distribution of bone
turnover to be synergistically monitored.
Although scaffolds provide a 3D environment and physical
cues for cells, the materials used to fabricate them are often
dissimilar to natural bone tissue. Additionally, scaffolds may
be doped with bioactive factors such as BMPs. Although
beneficial for tissue engineering, the presence of these foreign,
unrepresentative materials and factors may be obstructing the
investigation of the actual sequence of cellular events that
occur in vivo during remodelling. With this impetus, Clarke,
et al., attempted to create a scaffold-free three-dimensional
in vitro bone model by forming tissue aggregates in a rotational
bioreactor. Tissue constructs were formed by culturing human
osteoblasts and MNCs at a 2:1 ratio in media supplemented with
exogenous RANKL and M-CSF with the rotational speed varied
to alter initial aggregate size and keep the aggregate in free-fall
for up to 21 days. Mineralised, solid to the touch aggregates
up to 4mm could be formed after 3 weeks. These contained a
mineralised core with structures that resemble trabeculae which
contained embedded cells that express sclerostin, indicating
they may have become osteocytic. Surrounding the core,
a morphologically different perimeter that contained active
osteoblasts and osteoclasts expressing osteocalcin and TRAP,
respectively, was apparent and appeared to have resorption pits.
BMP-2, -4, and -7 expression was also detectable, as you would
expect with remodelling bone in vivo (Clarke et al., 2013).
Penolazzi, et al., also utilised a rotational bioreactor in
their in vitro remodelling system to simulate the jawbone
FIGURE 8 | Osteoclasts within a 3D human osteoblast and osteoclast co-culture taken by (A) confocal laser scanning microscopy (cLSM) (actin—green,
nuclei—blue) after 42 days and (B) SEM after 28 days. Osteoclast podosomes appear as dots within the cells by cLSM and thin filopodia are visible around the cell
perimeter. Figure adapted from (Heinemann et al., 2011) under The Creative Commons Attribution–ShareAlike License (CC-BY-SA).
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FIGURE 9 | Non-invasive methods of assessing bone turnover in vitro. SVF
cells can commit to osteoblastic and endothelial lineages. CD14+ cells
differentiate to osteoclasts. Cell culture supernatants were analysed for (A)
CICP, indicative of collagen synthesis, (B) TRAP, indicative of osteoclastic cells,
(C) NTX, indicative of collagen resorption, (D) phopshate levels, where
decreasing levels are indicative of mineralised matrix deposition and increasing
levels are indicative of mineralised matrix resorption (*p < 0.05). Figure
adapted from (Papadimitropoulos et al., 2011) under The Creative Commons
Attribution-ShareAlike License (CC-BY-SA).
microenvironment in the study of osteonecrosis of the jaw
(ONJ), a rare side effect associated with bisphosphonate
therapy. They extracted human osteoblasts from either healthy
donors or patients undergoing treatment for ONJ and co-
cultured them with human MNCs either indirectly or directly
without exogenous RANKL and M-CSF. Indirect cultures were
performed using well inserts. Direct co-cultures were either static
or dynamic. Direct-static cultures were performed by generating
spheroids of osteoblasts and MNCs in a 1:2 ratio on agarose-
coated well plates. Direct-dynamic aggregates were formed in
a rotational bioreactor at the same ratio. Indirect co-culture
generated multinucleated, TRAP and CTSK positive osteoclasts,
indicating the production of sRANKL. Static and dynamic direct
cultures had no difference in cell viability. As with Clarke
et al. aggregates within the rotational reactor had a much more
defined, better organised structure with three distinct regions.
Osteoblast markers OPN, OSX, Runx2, and ARS were all higher
in the dynamic culture, as were osteoclast markers TRAP and
CTSK. Osteoblasts from ONJ patients were lower in quality
but still able to form mineralising, TRAP positive aggregates
(Penolazzi et al., 2016).
The same group used this rotational bioreactor system to
explore the effect of menaquinone-4 (MK-4), a member of the
vitamin K2 family that can regulate calcium homeostasis andmay
have an anabolic effect on bone formation. Human amniotic fluid
MSCs (hAFMSCs) were co-cultured with human MNCs in a 2:1
ratio without exogenous RANKL and M-CSF. In conventional
2D and dynamic 3D monocultures of hAFMSCs, 10µM of
MK-4 significantly increased mineralisation and ALP, RUNX2,
OC, COL-1, and OPN mRNA expression without affecting
cell viability. In dynamic 3D co-culture hAFMSCs supported
osteoclastogenesis without exogenous factors, again in the outer
perimeter of the aggregate. In the presence of MK-4, there
were significantly fewer TRAP positive osteoclasts formed and a
significant increase in mineralised matrix deposition (Mandatori
et al., 2017).
Young et al. explored how the surface features of the substrate
can influence bone remodelling in vitro by performing co-
cultures on a polycarbonate surface either with or without
their previously developed “NSQ50” nanotopography. This
disordered but controlled surface has been demonstrated to
induce osteoblast differentiation fromMSCs with similar efficacy
to traditional osteogenic media (Dalby et al., 2007). Human
bone marrow was aspirated and separated into MSCs and
haematopoietic cells. MSCs were cultured on the substrates
for 1 week before the addition of the haematopoietic cells,
and then cultures were maintained for a further 3 weeks
with no exogenous osteoclastogenic supplements. After 21
days, large, TRAP positive, multinucleate osteoclasts with actin
rings were visible on both substrates, as well as smaller
TRAP positive mononuclear macrophages. There were no
significant differences in osteoclastogenesis between planar and
NSQ50 substrates as quantified by microscopy and TRAP,
OSCAR, and CTSK mRNA expression. However, the patterned
substrates stimulated increased bone mineral deposition over
the planar as demonstrated by alizarin red S and osteopontin
staining. RANKL, OPG, and IL-6 expression were significantly
increased on the NSQ50 surfaces but by equal amounts,
maintaining the RANKL:OPG ratio (Young et al., 2015). The
increase in osteoblast activity and mineral production without
a subsequent increase in osteoclast activity suggests that certain
nanotopographies can be selectively bioactive, influencing only
one cell type. Furthermore, this work has potential applications
in implant osseointegration and biomaterials that can stimulate
bone restoration in patients with osteoporosis.
Healthy bone remodelling requires a delicate balance between
formation and resorption by BMUs. These require a blood supply
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which is essential for delivery of nutrients, precursors and waste
removal. However, due to the complexity of angiogenesis in vitro,
this aspect of remodelling is often overlooked. We know that
the microvascular cells at sites of bone turnover can influence
osteoclastogenesis, and therefore including vascularisation is
essential in the attempt to mimic remodelling in vitro (Collin-
Osdoby et al., 2001). To address this, Bongio, et al., tetra-
cultured human umbilical vein endothelial cells (HUVECs),
MSCs, MSCs differentiated into osteoblasts, and human MNCs
within collagen/fibrin hydrogels incorporated with calcium
phosphate nanoparticles in media supplemented with exogenous
RANKL and M-CSF. Formation of microvessels was confirmed
in hydrogels in co-cultures of HUVECs andMSCs.Monocultures
of osteoblasts expressed raised proliferation, ALP activity and
mineralisation over time, and monocultures of osteoclasts
became TRAP positive and were able to resorb the matrix,
releasing phosphate into the media. Comparing vascularisation
in HUVEC-MSC vs tetra-culture, the presence of osteoblasts and
osteoclasts appeared to diminish overall hydrogel vascularisation,
with fewer but longer microvessels in the network. MSC
cells appeared to differentiate into mural cells to support the
vascular network. Comparing osteoblast/osteoclast co-cultures to
the tetra-culture, the latter enhanced osteoblast and osteoclast
differentiation over co-cultures, as indicated by ALP and TRAP
activity and phosphate release (Bongio et al., 2016). The presence
of MSCs and HUVECs within the culture positively influenced
osteogenic and osteoclastic differentiation, with all four cell types
synergistically influencing each other.
DISEASE-ORIENTATED MODELS
Simpler, two-dimensional co-cultures of osteoblasts and
osteoclasts can help us elucidate factors that regulate the
remodelling process, and by moving to more physiologically
relevant three-dimensional systems we have seen the creation
of increasingly complex in vitro models of the entire process.
These will become invaluable in understanding how this
intricate process occurs, as well as for evaluating potential new
therapeutics and implants. However, such models also have the
capacity to be adapted to study various pathologies, including
cancer, osteoporosis and dental disorders.
Cancer
Multiple myeloma is a type of cancer characterised by
accumulation of plasma cells in the bone marrow and formation
of osteolytic lesions due to greater osteoclast activity and
reduced osteoblast activity (Giuliani et al., 2014). BRCs typically
separate the BMU from the bone marrow to regulate the
microenvironment and tightly control osteoblast-osteoclast
coupling and therefore ensure balanced remodelling (Eriksen,
2010). However, in biopsies from patients with MM areas of
uncoupled and therefore excessive resorption, which results in
the formation of osteolytic lesions, have compromised BRCs
which permit the passage of MM cells. Uncompromised areas
had normal bone remodelling as the BRCs acted as a barrier to
the cancerous cells (Andersen et al., 2009). To elucidate whether
the formation of these lesions was indeed due to compromised
BRCs, Anderson et al. attempted to create an in vitro model of
the scenario. They utilised a confluent G0-arrested monolayer of
MC3T3-E1 to simulate the BRC. Direct contact with OPM2MM
decreased the surface area covered by the MC3T3-E1, whereas
indirect co-culture using a well insert had no effect. Conversely,
direct co-culture with humanMNC-derived osteoclasts increased
the area covered (Andersen et al., 2010). This indicates that MM
cells may be able to disrupt the BRC in direct cell contact.
Prostate cancer (PCa) is one of the most common cancers
and has a high mortality rate due to the development of
hematogenous metastases. Approximately 90% of these occur
within bone, with 85–100% of patients who die from prostate
cancer having bonemetastases (Bubendorf et al., 2000; Carlin and
Andriole, 2000; Pentyala et al., 2000). To better understand how
PCa cells interact with the tissue, Nordstrand et al. developed an
in vitro co-culture model where monolayers of either PC-3, an
osteolytic human PCa cell line, or LNCaP, a human PCa cell line
with a mixed/osteoblastic phenotype, were cultivated beneath
a freshly harvested murine calvarial bone that still contained
osteoblasts and osteoclasts. PC-3 upregulated CTSK, TRAP,
MMP-9, and RANKL mRNA expression whilst inhibiting OPG,
ALP and osteocalcin expression, causing a negative bone balance
by increasing the RANKL:OPG ratio and decreasing osteoblast
activity. In contrast to the osteolytic activity of PC-3, LNCaP
raised ALP and osteocalcin expression and had no significant
effect on the RANKL:OPG ratio in comparison to control
calvarial cultures, indicating a small shift toward a positive bone
balance (Nordstrand et al., 2009). By utilising ex vivo tissue in
the co-culture the natural heterogeneity of the cell population in
the bone tissue was maintained. This results in an in vitromodel
that can be used to study the interaction between PCa cells and
bone. Li et al. also utilised PC-3 and C4-2B, a subline of LNCaP,
to examine how PCa metastases influence remodelling. In both
cell lines, TGF-β heightened RANKL expression and RAW264.7
differentiation, indicating PCa cells can induce osteoclastogenesis
(Li et al., 2012).
Breast cancer (BCa) is another very common cancer that
regularly develops bone metastases. These metastases cause a
negative bone balance by increasing osteoclast activity. This
releases cytokines and growth factors from the resorbed bone,
which in turn stimulates cancer cell proliferation, which further
exacerbates the resorption. This vicious cycle results in significant
bone loss, pain and morbidity (Chen et al., 2010; Desantis et al.,
2013). To investigate this, Krishnan, et al., introduced metastatic
breast cancer cells to an in vitro bone remodelling model.
Using a bioreactor they developed for long-term (<10 months)
osteoblast culture, they maintainedMC3T3-E1 for 60 days before
the addition of pre-osteoclasts harvested from murine bone
marrow (Krishnan et al., 2010). MDA-MB-231-GFP BCa cells
were added to the co-culture after a further 10 days. Cultures were
maintained in media containing exogenous RANKL and M-CSF.
After 60 days, the MC3T3-E1 had created and become embedded
in a thick, collagenous ECM. After a further 21 days of osteoclast
culture, multinucleated, TRAP positive osteoclasts that resorbed
the ECM and formed pits were visible. Subsequent addition of
new MC3T3-E1 resulted in the refilling of the resorbed areas,
completing the remodelling process. After the initial 60 days,
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FIGURE 10 | Requirements for a robust in vitro model of bone remodelling.
A 3D co-culture of osteoblast- and osteoclast-lineage cells where the
osteoblastic component are capable of endogenously producing RANKL,
M-CSF and OPG. The model is cultured in a defined, serum-free medium
containing physiologically relevant concentrations of important hormones, e.g.,
oestrogen, to permit the study of associated disorders such as
postmenopausal osteoporosis. The culture can be mechanically loaded using
varying force levels, for example by compression or application of fluid flow.
the ECM was 20µm thick. This was reduced to 16.5µm by the
addition of osteoclasts and 14.5µm by osteoclasts and BCa cells.
The metastatic cells penetrated the ECM and formed osteoclasts-
BCa aggregates, as well as increasing osteoclastogenesis and
downregulating osteoblast differentiation in comparison to co-
cultures (Krishnan et al., 2014, 2015). This model without
the BCa cells includes the major processes of remodelling,
albeit requiring the addition of new osteoblast pre-cursors, and
provides a way of studying the process over long time periods.
The addition of BCa cells provides a simplified platform for the
study of how the major cellular constituents of breast cancer
metastases interact.
The cannabinoid type 2 (CB2) receptor has been implicated
with regulating tumour growth and bone remodelling. By
agonising this receptor with JWH133 or HU308, Sophocleous,
et al., determined that the growth of three BCa cell lines
could be inhibited, but that the agonists have no effect on the
proliferation of murine calvarial osteoblasts or bone marrow-
derived osteoclasts. In co-cultures of the bone cells, conditioned
media from the cancer cells upregulated osteoclastogenesis in
comparison to untreated controls; however, treatment with
the CB2 agonists further enhanced osteoclast formation by
increasing the RANKL:OPG ratio. Treatment of osteoclast
monocultures with the agonists and conditioned media raised
osteoclast formation, TRAP and CTSK expression and resorption
in comparison to conditioned media alone (Sophocleous et al.,
2015). These findings indicate that although CB-2 activation
has been shown to supress cancer cell proliferation and tumour
growth at higher concentrations, lower concentrations enhanced
osteolysis in this study, and therefore CB-2 inhibition may
protect the skeleton in cases of BCa metastases (Lozano-Ondoua
et al., 2013).
Trichostatin A (TSA) is an antibiotic that acts as an
inhibitor of histone deacetylase enzymes that regulate chromatin
remodelling and transcription activity, rendering it a potent
anticancer drug. In co-cultures of murine osteoblasts and
red blood cell free murine bone marrow cells, 10 nM TSA
significantly reduced osteoclast formation but it did not alter
the RANKL:OPG ratio. Instead, it acts directly on osteoclast
precursors by downregulating c-fos, a transcription factor
essential in osteoclastogenesis. In vivo, they found TSA can
mitigate IL-1 induced bone loss, indicating this drug may also
have potential in reducing inflammatory bone loss (Kim et al.,
2009).
Dental Disorders
Cleidocranial dysplasia (CCD) is a congenital disorder that
affects bone and tooth development due to mutations in the
RUNX2 gene. For a tooth to erupt a path must be cleared
through the bone above via resorption. Eruption is delayed
in patients with CCD, therefore Lossdörfer et al. invesitgated
whether this was due to PDL cells from CCD pateints having
reduced capability to induce osteoclastogenesis. Human PDL
cells from healthy of CCD patients were co-cultured with
RAW264.7 in a 1:1 ratio. Vitamin D3 increased the RANKL:OPG
ratio in both healthy and diseased PDL cells. Conditioned
media from healthy PDL cells produced significantly more TRAP
positive, multinucleated osteoclasts. In direct co-culture, PDL
cells from CCD patients reduced TRAP and CTSK expression in
comparison to healthy PDL cells (Lossdörfer et al., 2009). Yan
et al. also investigated the delayed eruption of teeth in CCD
by co-cultruing primary human dental pulp cells (DPCs) from
healthy or CCD patients with hPBMCs. ALP expression and
formation of mineralised nodules was reduced in CCD DPCs.
In co-culture, TRAP, CTSK, and MMP-9 exression were all
reduced in comaprison to healthy DPCs due to a 92% reduction
in the RANKL:OPG ratio (Yan et al., 2015). The findings of
Wang, et al., agree with both these studies. They co-cultured
healthy or CCD patient dental follicle cells (DFCs) with hPBMCs,
finding that diseased cells had a reduced capability to induce
osteoclast formation through a reduction in the RANKL:OPG
ratio. However, Vitamin D3 was only able to increase the ratio
in DFCs from healthy donors as its stimulation of RANKL
production is mediated prinicpally by a RUNX2 deppendent
pathway (Wang et al., 2016). These data combine to indicate
that the primary teeth retention associated with CCD may
be due to a reduced capacity of osteoblast-like dental cells to
induce osteoclastogenesis and create a path for teeth to emerge
through.
Testing of Anabolic Therapeutics
Osteoporosis is the most common metabolic bone disorder but
as it stands there is no in vitro model for the study of the
disease. Despite this, in vitro models of remodelling can be used
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to study potential new anabolic therapeutics for the disorder.
Icariin is a phytoestrogen and a flavonoid in Herba epimedii
that can stimulate bone formation and inhibit osteoclastogenesis
(Huang et al., 2007). Liu et al. investigated whether it can have a
synchronised duel effect on osteoblasts and osteoclasts in a direct
co-culture of murine MSCs and RAW264.7 with exogenous
RANKL and M-CSF and ovarian follicular granulosa cells (GC)
in a well insert above. Co-cultures had greater ALP staining in
comparison to murine OBmono-cultures, indicating osteoclastic
upregulation of osteoblasts. This was further amplified when
GC cells were present, and the co-culture raised the oestradiol
production of the GC cells. There was no change in the amount of
TRAP positive osteoclast formation in co-culture over osteoclast
monoculture. Icariin was compared to common osteoporosis
drugs to evaluate its efficacy. In co-culture, alendronate, a
bisphosphonate, reduced both TRAP and ALP activity and PTH
increased both TRAP and ALP activity. However, Icariin reduced
TRAP and raised ALP activity. A similar effect was seen when
substituting RAW264.7 for murine peripheral blood monocytes
(Liu et al., 2015). These findings in combination with a recent
ovariectomy (OVX) study indicate its potential as an anabolic
therapeutic for osteoporosis (Wang et al., 2017).
Semaphorins are a class of membrane-bound or secreted
proteins involved in osteoclast-osteoblast communication.
Osteoclast-derived semaphorin 4D (sema4D) binds to its
receptor Plexin-B1 on osteoblasts, inhibiting bone formation
(Negishi-Koga et al., 2011). Therefore, it has the capability
to regulate bone turnover, and overexpression of sema4D is
observed in osteoporosis. Zhang et al. utilised siRNA to interfere
with sema4D and create a targeted drug delivery system. By
applying the siRNA to co-cultures of murine osteoblasts with
bone-marrow derived osteoclast precursors, they found that
application of the siRNA does not influence osteoclast number or
function, but ALP, COL-1, and osteocalcinmRNA expression and
mineralised matrix formation are increased in silenced cultures.
When used in vivo in OVX mice, regular administration of
the siRNA had similar results to that observed in vitro by
significantly increasing the number of active osteoblasts and
total bone volume, indicating sema4D silencing as a potential
therapeutic option for osteoporotic patients (Zhang et al., 2015).
CONCLUSIONS
An established, human-based in vitromodel of bone remodelling
is an exciting prospect due to the range of benefits it can
provide. There is currently a poor translation of pre-clinical
efficacy in animal models to human trials, meaning that there is a
need for an alternative method of screening and evaluating new
therapeutics for metabolic bone disorders. Such a model could
provide a platform suitable for this that would have reduced
financial and ethical costs in comparison to in vivo models.
Furthermore, it could be utilised in the study of diseases that
also affect the skeleton, such as metastatic cancers and dental
disorders. Finally, it could improve our understanding of how
materials will behave once implanted into the body, as well as the
remodelling process itself.
To date, a range of in vitro studies have helped elucidate
the mechanisms and biological factors by which our bones
remodel. When combined with the recent advances in bone
tissue engineering, this has given rise to increasingly complex
systems that to some extent can mimic remodelling in vitro.
However, despite creating functional three-dimensional systems,
we are not yet in a position where the remodelling process
in vitro can be truly recreated. Perhaps the greatest limitation
of much of work performed thus far is the reliance on
the addition of exogenous RANKL to the co-cultures. When
diseases such as osteoporosis disrupt our bone balance, it
is predominantly through an alteration in the RANKL:OPG
ratio. Therefore, when this mechanism is overridden by adding
RANKL exogenously, the possibility of utilising the resulting
system in the study of these diseases is removed. Superficially,
this limitation seems simple to overcome—simply utilise the
osteoblast-lineage cells endogenous ability to produce RANKL.
Regrettably, it is not as straightforward this. Although there are
a small handful of studies that have successfully exploited this
(Lossdörfer et al., 2009, 2011; Tortelli et al., 2009; Heinemann
and Heinemann, 2011; Penolazzi et al., 2016; Mandatori et al.,
2017); the majority have found that without exogenous addition
osteoclastogenesis will not occur. This could be for two reasons;
either RANKL is not being produced or such an excess of
OPG is being co-synthesised that the resulting ratio inhibits
osteoclast differentiation. Considering the first possibility, studies
where cells produced sufficient endogenous RANKL had one
thing in common—they were all primary cells. Therefore, it
could be that its synthesis is highly donor specific. Alternatively,
it could be that some essential factor is missing from the
media. However, the general composition is highly similar
making this unlikely, making it more likely that it is some
factor present or absent in the serum. Whether either of
these are the case, or whether it is the result of excessive
OPG production, it is clear that a cell source capable of
synthesising RANKL reproducibly and a defined, serum-free
media composition are essential for a robust in vitromodel to be
developed.
Two final considerations that should be accounted for in
future work are mechanical stimulation and the hormones
involved in remodelling, specifically oestrogen (Figure 10).
Mechanical loading modulates remodelling in vivo and therefore
should be incorporated into a representative model (Robling
and Turner, 2009). This would permit the study of the effects
changes in loading on bone in vitro. By utilising a culture
media for the model that has a representative concentration of
hormones knows to affect bone metabolism, there would be the
possibility of modulating this to study associated disorders such
as postmenopausal osteoporosis. Such an in vitro model of bone
remodelling would perhaps have the greatest potential impact on
the use of animals in musculoskeletal research.
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